Fighting neurodegenerative disease

with new therapies emerging from ground-breaking research relating to repeat associated non-ATG (RAN) Translation

Explore Contact Us

RanTran is a development stage company whose mission is to investigate, develop and commercialize therapies to fight neurodegenerative disease, one of the cruelest killers of all.

Learn more about RanTran

Publications, Articles & News

Press Releases Potential treatment pathway for genetic form of ALS and FTD Read More

News Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS/FTD mice Read More

RANTRAN impact. Developing and commercializing RNA therapies to restore protein function.

IMPACT OF RESEARCH

The identification and manipulation of pathways that block RAN translation or target RAN proteins using gene therapy can be developed as a platform technology to fight C9orf72 ALS/FTD and a large category of other diseases involving RAN proteins.